Navigation Links
Chlamydia vaccine a step closer to reality

Scientists at Queensland University of Technology are one step closer to developing a world-first vaccine to protect women against contracting the most common sexually-transmitted disease, Chlamydia.

International vaccine company Sanofi-Pasteur has awarded QUT a funding boost of more than $300,000 to continue its research into Chlamydia and work towards developing a vaccine specifically targeting adolescent women.

Professor Peter Timms, from QUT's Institute of Health and Biomedical Innovation (IHBI), said a team of researchers had already identified certain proteins that were able to protect against Chlamydia infection.

"We've been testing these proteins as part of animal trials...and we think we've got the answer. It is possible that within three to five years we'll be finished the animal trials and be looking at clinical trials in humans."

Professor Timms said Sanofi-Pasteur's funding would allow QUT to evaluate the effectiveness of Chlamydia prevention methods developed at the university, as well as compare and test possible prevention methods being developed by Sanofi-Pasteur.

He said once a vaccine had been developed it could be administered via a patch, similar to ones used by smokers for nicotine.

"Patches are a good way to deliver proteins to a part of the body's immune system and they are also easy and user-friendly."

He said with rates of Chlamydia infection in some Australian communities as high as 12 per cent of the female population, there was a "real need" to develop a vaccine.

"Chlamydia is the most common infectious disease in the world and results in infertility in women and long-term chronic pelvic pain," he said.

"There are antibiotics to treat Chlamydia, but there's no vaccine to prevent it. In many cases women don't know they are infected because there are not really any physical signs or symptoms, so by and large they don't get treatment."

Professor Timms said Sanofi-Pasteur was one of the world's largest companies devoted to the development of human vaccines.

"The fact that such a large vaccine company as Sanofi-Pasteur has selected QUT to help develop Chlamydia vaccines points to the value of the work being done here," he said.

"Despite this current injection of funds, further work and funding is still needed to take this current research through to a vaccine product."

QUT researchers working on the project are part of IHBI's Cells and Tissue Domain and include Professors Peter Timms, Ken Beagley, Associate Professor Louise Hafner, Celia Berry and Chris Barker.


Source:Queensland University of Technology

Related biology news :

1. Chlamydia parasite lives off our fat
2. Research advances quest for HIV-1 vaccine
3. A much-needed shot in the arm for HIV vaccine development
4. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
5. Gene vaccine for Alzheimers disease shows promising results
6. Influenza vaccine uses insect cells to speed development
7. Norovirus, AIDS vaccine and Hepatitis Virus
8. HIV vaccine trial breaks ground for future research
9. Live vaccines more effective against horse herpes virus
10. NIAID begins clinical trial of West Nile virus vaccine
11. Designing vaccines by computer
Post Your Comments:

(Date:6/27/2016)... June 27, 2016 Research and Markets has ... 2016-2020" report to their offering. ... America to grow at a CAGR of 12.28% during ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:6/22/2016)... American College of Medical Genetics and Genomics was once again ... of the fastest-growing trade shows during the Fastest 50 Awards ... Las Vegas . Winners are ... of the following categories: net square feet of paid exhibit ... 2015 ACMG Annual Meeting was ranked 23 out of 50 ...
(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... Lemonade Stand Foundation (ALSF), a leading national childhood cancer ... bioinformatics lab, using ,big data, to advance the pace ... Liz Scott , co-executive director of ALSF and Alex,s ... Washington, D.C. , hosted by Vice President ... pediatric cancer research and awareness. The ...
(Date:6/27/2016)... , June 27, 2016  Global demand for ... percent through 2020 to $7.2 billion.  This market ... beverages, cleaning products, biofuel production, animal feed, and ... diagnostics, and biocatalysts). Food and beverages will remain ... by increasing consumption of products containing enzymes in ...
(Date:6/27/2016)... ON , June 27, 2016 /PRNewswire/ - BIOREM Inc. ... has been advised by its major shareholders, Clean Technology ... United States based venture capital ... shares of Biorem (on a fully diluted, as converted ... the disposition of their entire equity holdings in Biorem ...
(Date:6/27/2016)... SAN DIEGO , June 27, 2016  Sequenom, ... company committed to enabling healthier lives through the development ... Supreme Court of the United States ... Federal courts that the claims of Sequenom,s U.S. Patent ... the patent eligibility criteria established by the Supreme Court,s ...
Breaking Biology Technology: